Immunitybio Inc. logo

IBRX

Immunitybio Inc.

$5.96

Earnings Summary

Revenue
$0.04Mn
Net Profits
$-134.11Mn
Net Profit Margins
-335272.5%

Highlights

Revenue:

Immunitybio Inc.’s revenue fell -88.89% since last year same period to $0.04Mn in the Q1 2024. On a quarterly growth basis, Immunitybio Inc. has generated -71.22% fall in its revenue since last 3-months.

Net Profits:

Immunitybio Inc.’s net profit jumped 11.28% since last year same period to $-134.11Mn in the Q1 2024. On a quarterly growth basis, Immunitybio Inc. has generated 42.54% jump in its net profits since last 3-months.

Net Profit Margins:

Immunitybio Inc.’s net profit margin fell -698.47% since last year same period to -335272.5% in the Q1 2024. On a quarterly growth basis, Immunitybio Inc. has generated -99.68% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Immunitybio Inc. post its latest quarter earnings

EPS Estimate Current Year
-0.16

Highlights

EPS Estimate Current Year:

Immunitybio Inc.’s earning per share (EPS) estimates for the current year stand at -0.16.

Key Ratios

Key ratios of the Immunitybio Inc. post its Q1 2024 earnings

Earning Per Share (EPS)
-0.2
Return on Assets (ROA)
-0.58
Return on Equity (ROE)
0

Highlights

Earning Per Share (EPS):

Immunitybio Inc.’s earning per share (EPS) jumped 25.93% since last year same period to -0.2 in the Q1 2024. This indicates that the Immunitybio Inc. has generated 25.93% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Immunitybio Inc.’s return on assets (ROA) stands at -0.58.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Immunitybio Inc.’s return on equity (ROE) stands at 0.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2024-05-09
-0.16
-0.2
-25%